/

Società

Ep

Non verificato

Epirium Bio Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

7 comunicati stampa

Guarda tutti i comunicati

05/05/2026

Eventi

Scienza

Terza età

Biotecnologia

Farmaceutica

Salute

Vetrine/Shopping

Medicina - Varie

Epirium Bio Presenting New Preclinical Data on its 15-PGDH Inhibitor Program in Inflammatory Bowel Disease at Digestive Disease Week® 2026

Fonte

Epirium Bio Inc.

Emittente

1.00

0

12/03/2026

Eventi

Industria

Scienza

Terza età

Medicina - Varie

Biotecnologia

Salute

Vetrine/Shopping

Farmaceutica

Epirium Bio to Present New MF-300 Clinical and Translational Data at the Intrinsic Capacity, Frailty and Sarcopenia Research Conference 2026

Fonte

Epirium Bio Inc.

Emittente

1.00

0

27/01/2026

Scienza

Igiene alimentare

Terza età

Medicina - Varie

Biotecnologia

Salute

Vetrine/Shopping

Farmaceutica

Industria

Epirium Bio Announces Positive Type C (End-of-Phase 1) Meeting with FDA Supporting Advancement of MF-300 to a Phase 2b Clinical Trial in Sarcopenia

Fonte

Epirium Bio Inc.

Emittente

1.00

0

08/01/2026

Scienza

Terza età

Biotecnologia

Farmaceutica

Salute

Vetrine/Shopping

Medicina - Varie

Industria

Epirium Bio Announces Follow-on Phase 1 Results in Older Adult Participants for MF-300, a First-In-Class, Oral 15-PGDH Enzyme Inhibitor, for the Treatment of Sarcopenia

Fonte

Epirium Bio Inc.

Emittente

1.00

0

17/11/2025

Biotecnologia

Farmaceutica

Salute

Medicina - Varie

Eventi

Industria

Epirium Bio Presented Positive Phase 1 Safety, Pharmacokinetics and Pharmacodynamics Data for MF-300, Supporting its Role in Muscle Health, as a Late-Breaker at the Gerontological Society of America Annual Scientific Meeting 2025

Fonte

Epirium Bio Inc.

Emittente

1.00

0

24/09/2025

Industria

Scienza

Terza età

Medicina - Varie

Biotecnologia

Salute

Vetrine/Shopping

Farmaceutica

Epirium Bio Announces Positive Phase 1 Clinical Trial Results Evaluating MF-300 in Healthy Volunteers, A First-In-Class, Oral 15-PGDH Enzyme Inhibitor, For the Treatment of Sarcopenia

Fonte

Epirium Bio Inc.

Emittente

1.00

0

13/03/2025

Web e Social Network

Eventi

Industria

Scienza

Terza età

Biotecnologia

Farmaceutica

Salute

Vetrine/Shopping

Medicina - Varie

Epirium Bio to Present MF-300 Preclinical Data at the International Conference on Frailty and Sarcopenia Research

Fonte

Epirium Bio Inc.

Emittente

1.00

0

Seguaci

0

Compatibilità

0